NEW YORK (GenomeWeb News) – Life Technologies today announced it has acquired cancer bioinformatics firm Compendia for an undisclosed amount.

Based in Ann Arbor, Mich., Compendia develops products used by drug manufacturers for identifying novel gene targets in drug discovery and development, and according to Life Tech, its expertise in oncology and proprietary assets "enhance Life's diagnostic development capabilities across multiple platforms, including next-generation sequencing, qPCR, and proteome analysis."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.